GLP-1 receptor agonists and thyroid C-cell concerns — what worked for you?

This one has a reasonably settled answer, so here it is. The pharmacokinetics explain nearly every practical question asked here. Albumin binding above 99% slows clearance enough to make weekly dosing possible; a terminal half-life near a week means four to five weeks to steady state and therefore a four-week titration interval; subcutaneous bioavailability around 89% means injection site barely matters. Those three facts answer most timing questions before they are asked.

Dr.SurgeonPGH said:

The pharmacokinetics explain nearly every practical question asked here.

Agreed, and the adaptation point cuts both ways: tachyphylaxis to gastric emptying is why tolerability improves, and it is also why people who were relying on physical fullness feel the effect fade while the appetite effect is still working.

pam_columbus said:

My prescriber wanted a baseline TSH and did not want a calcitonin, and I would like to understand the reasoning rather than just accepting it.

Same experience, arrived at from the opposite direction. Posting only so the count is not one.

Clinical perspective, offered as context rather than as advice.

Thyroid cancer screening labs for thyroid monitoring — addressing the boxed warning concern with actual data:

Calcitonin level: 4.0 pg/mL (normal <10). Checked at baseline, month 6, and month 12. Rock stable, no upward trend.

Thyroid ultrasound: normal, no nodules at month 12.

The MTC risk from rodent studies has not been confirmed in human post-marketing data across millions of patient-years. The boxed warning is a regulatory precaution based on animal data. While monitoring is prudent, the clinical risk appears to be negligible.